Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Total Revenue
1,116,854
889,895
751,040
548,485
Cost of Revenue
209,620
152,008
129,764
95,742
Gross Profit
907,234
737,887
621,276
452,743
Operating Expenses
Research Development
661,905
634,806
461,543
354,780
Selling General and Administrative
476,593
402,271
302,156
235,356
Non Recurring
--
--
--
--
Others
572,165
(188,488)
(49,532)
18,614
Total Operating Expenses
1,710,663
848,589
714,167
608,750
Operating Income or Loss
(803,429)
(110,702)
(92,891)
(156,007)
Income from Continuing Operations
Total Other Income/Expenses Net
4,391
(38,773)
(1,272)
(13,132)
Earnings Before Interest And Taxes
(791,551)
(144,974)
(88,226)
(166,056)
Interest Expense
39,499
9,750
36,642
10,447
Income Before Tax
(831,050)
(154,724)
(124,868)
(176,503)
Income Tax Expense
(200,840)
17,075
9,101
(150)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(630,210)
(171,799)
(133,969)
(176,353)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(630,210)
(171,799)
(133,969)
(176,353)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(630,210)
(171,799)
(133,969)
(176,353)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information